Bill Wexler's Profits of DOOM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bill Wexler who wrote (151)	2/25/1998 9:56:00 PM
From: Bill Wexler	of 4634

Zonagen accelerates its price decline. The following is excerpted from the Manuel Asensio report on Zonagen: COMPANY BACKGROUND Zonagen was founded to develop an alternative to the surgical spaying of cats and dogs. Based on the prospects for a "genetically engineered vaccine that could replace surgical spaying," Zonagen was able to arrange a IPO through Reich & Company, Inc. Zonagen never developed or sold any such product. On April 14, 1994, Zonagen acquired certain rights related to phentolamine from Dr. Adrian Zorgniotti and Gamogen, Inc. Zonagen owns no pharmaceutical manufacturing capacity. As of September 30, 1997,Zonagen had accumulated losses of over $41.4 million. These losses have been funded through a series of stock offerings. Zonagen has never received approval or announced a filing of an NDA for any drug.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next